| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
Journal of the American Society of Nephrology, Vol 5, 1740-1744, Copyright © 1995 by American Society of Nephrology
REVIEWS |
MG Parker, MB Atkins, AA Ucci and AS Levey
Division of Nephrology, New England Medical Center, Boston, MA, USA.
Cytokines have been used in experimental and standard protocols for immune enhancement for cancer. The combination of interleukin-2 and interferon-alpha 2 beta has been used in experimental protocols for metastatic renal cell carcinoma. A man who developed rapidly progressive renal failure after receiving this combination therapy is reported. A renal biopsy revealed a pauci-immune crescentic glomerulonephritis. Antineutrophil cytoplasmic antibodies and antiglomerular basement membrane antibodies were absent. The spectrum of renal disease and potentially related extrarenal manifestations associated with interleukin-2 and inteferon-alpha are reviewed. A pathogenesis of altered cell-mediated immunity, consistent with abnormalities in extrarenal organs after immune enhancement, is proposed.
This article has been cited by other articles:
![]() |
J. Lechner, N. Malloth, T. Seppi, B. Beer, P. Jennings, and W. Pfaller IFN-{alpha} induces barrier destabilization and apoptosis in renal proximal tubular epithelium Am J Physiol Cell Physiol, January 1, 2008; 294(1): C153 - C160. [Abstract] [Full Text] [PDF] |
||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673